Clinical trials: Dyspareunia
Menopause, Vulvovaginal Atrophy
TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy
The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and…
- Conditions
- Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
- Trial name
- NCT02449902
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- TherapeuticsMD
Vulvovaginal Atrophy
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
- Trial name
- NCT01845649
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 57 sites in United States
- Volunteers
- 550 people
- Sponsor
- Warner Chilcott
Endometriosis
A Study to Evaluate the Safety and Effectiveness of Three Asoprisnil Doses in the Treatment of Women With Endometriosis
The objective of this study is to determine the safety and effectiveness of three doses of asoprisnil, compared to placebo, in the treatment of women with endometriosis.
- Trial name
- NCT00160446
- Testing
- Asoprisnil
- Volunteers
- 130 people
- Sponsor
- Abbott
Female Dyspareunia
A Study of Participants Ages 21-65 Diagnosed With Dyspareunia and the Effects of Low Intensity Shockwave Treatment
Dyspareunia is defined as a complaint of persistent or recurring pain or discomfort associated with attempted or complete vaginal penetration e purpose of this study is to determine the effectiveness of low intensity shockwave…
- Trial name
- NCT05806203
- Testing
- Low intensity shockwave treatment to pelvic floor region plus typical physical therapy
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- SoftWave Tissue Regeneration Technologies
Atrophic Vaginitis, Atrophic Vulvovaginitis
F-GYN for Vaginal Dryness and Vulvovaginal Atrophy
This clinical study will evaluate the efficacy and safety of F-GYN, a sterile injectable medical device containing non-crosslinked hyaluronic acid, in adult women with moderate to severe vaginal dryness and symptoms related to…
- Conditions
- Atrophic Vaginitis, Atrophic Vulvovaginitis, Vaginal Atrophy, Dyspareunia
- Trial name
- F-GYN (NCT07701863)
- Testing
- F-GYN Non-Crosslinked Hyaluronic Acid Injectable Gel, Standard Non-Hormonal Symptomatic Care
- Where
- 3 sites in Poland
- Volunteers
- 130 people
- Sponsor
- Biovico Sp. z o.o.
Dyspareunia, Vaginal Dryness
Effectiveness and Safety of a Water-based and a Silicone-based Personal Lubricants With Sensory Action
This clinical investigation will look at the effectiveness and safety of two personal lubricants for the relief of intimate discomfort associated with vaginal dryness.
- Trial name
- NCT05644444
- Testing
- Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant), Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)
- Where
- Germany
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Dyspareunia, Vaginal Dryness
A Clinical Investigation Into the Effectiveness and Safety of Five Water Based Personal Lubricants.
This clinical investigation will look at the safety of five water based personal lubricants, and teir effectiveness the relief of intimate discomfort associated with vaginal dryness.
- Trial name
- NCT04908124
- Testing
- Lubricant A, Lubricant B, Lubricant C
- Where
- Germany
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Endometriosis
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
- Trial name
- EDELWEISS (NCT02778399)
- Testing
- OBE2109
- Where
- 86 sites in United States, Poland and 2 more
- Volunteers
- 328 people
- Sponsor
- ObsEva SA
Endometriosis, Dysmenorrhea
Pertubation With Lignocaine in Endometriosis
Endometriosis is a disease of unknown aetiology that can cause severe dysmenorrhea. An altered immune system with elevated levels of cytokines in the peritoneal fluid as well as increased density of nerve fibres, might explain…
- Trial name
- PLEASE (NCT01329796)
- Testing
- Lignocaine, Ringers Solution
- Where
- 3 sites in Sweden
- Volunteers
- 42 people
- Sponsor
- Isifer AB
Endometriosis
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis associated pain in adult pre-menopausal women who completed 6 months treatment in pivotal Study…
- Trial name
- NCT02143713
- Testing
- Elagolix
- Volunteers
- 496 people
- Sponsor
- AbbVie
Vaginal Atrophy, Vulvovaginal Signs and Symptoms
Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.
The study is an open-label uncontrolled single-center study for the evaluation of the Performance characteristics (efficacy and safety) of the dermal filler "MMG-23-04-2019" on the female genital area for the medicinal…
- Conditions
- Vaginal Atrophy, Vulvovaginal Signs and Symptoms, Dyspareunia, Urinary Incontinence
- Trial name
- NCT04659668
- Testing
- MMG-23-04-2019
- Where
- Bulgaria
- Volunteers
- 37 people
- Sponsor
- Mesoestetic Pharma Group S.L.
Menopause
A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy
This is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of Enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal…
- Trial name
- NCT00196378
- Testing
- Synthetic Conjugated estrogens, B
- Where
- 38 sites in United States
- Volunteers
- 300 people
- Sponsor
- Duramed Research
Dyspareunia
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.
- Trial name
- NCT05617820
- Testing
- Estradiol, Imvexxy
- Where
- 48 sites in United States, El Salvador and 1 more
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Vaginismus, Dyspareunia
Prospective on Market Patient-reported Outcomes for Milli
To assess the effectiveness of the Milli device in achieving vaginal intercourse
- Trial name
- POMPOM (NCT06397885)
- Testing
- Milli Vaginal Dilator
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Materna Medical
Vulvovaginal Atrophy, Menopause
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.
- Conditions
- Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
- Trial name
- REJOICE (NCT02253173)
- Testing
- Estradiol
- Where
- 105 sites in United States, Canada
- Volunteers
- 764 people
- Sponsor
- TherapeuticsMD
Endometriosis
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have…
- Trial name
- NCT04335591
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 47 sites in United States, Austria and 7 more
- Volunteers
- 356 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Menopausal and Perimenopausal Disorder, Unspecified, Atrophic Vaginitis
Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness
This is a pilot study, assessing the ability and safety of the use of VR101 intravaginal ring to relieve the symptoms of vaginal dryness, in peri and post-menopausal women. VR1010 is designed to release glycerol.
- Trial name
- NCT02029053
- Testing
- Vaginal Lubrication Ring for Vaginal Dryness
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- J3 Bioscience, Inc.
Vulvo Vaginal Atrophy (VVA)
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Study Objectives: Primary: To assess the safety, tolerability, and systemic pharmacokinetics (PK) of AZU-101 Secondary: To evaluate efficacy of daily vaginal doses of AZU-101 in postmenopausal women on vaginal epithelium
- Trial name
- NCT06197568
- Testing
- Lasofoxifene Tartrate
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Azure Biotech Inc.
Endometriosis
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03986944
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 112 sites in United States, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Vaginal Atrophy, Sexual Dysfunction
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.
- Conditions
- Vaginal Atrophy, Sexual Dysfunction, Dyspareunia, Vaginal Dryness
- Trial name
- NCT03178825
- Testing
- Hybrid Fractional Laser
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sciton